QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma

Summary

This is a single-arm, Simon's two-stage phase II clinical trial to evaluate the efficacy and safety of QL1706 (a dual PD-1 and CTLA-4 antibody) combined with celecoxib in patients with advanced esophageal squamous cell carcinoma (ESCC) who progressed after prior immune checkpoint inhibitor therapy.

Timeline

Start

2025-07-15

Primary completion

2027-03-01

Completion

2027-09-01

Drugs

Indications